Better Therapeutics Stock Market Capitalization
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Better Therapeutics fundamentals help investors to digest information that contributes to Better Therapeutics' financial success or failures. It also enables traders to predict the movement of Better OTC Stock. The fundamental analysis module provides a way to measure Better Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Better Therapeutics otc stock.
Better |
Better Therapeutics OTC Stock Market Capitalization Analysis
Better Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Better Therapeutics Market Capitalization | 1.12 M |
Most of Better Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Better Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Better Therapeutics is about 1.12 M. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The market capitalization for all United States stocks is 99.99% higher than that of the company.
Better Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Better Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Better Therapeutics could also be used in its relative valuation, which is a method of valuing Better Therapeutics by comparing valuation metrics of similar companies.Better Therapeutics is currently under evaluation in market capitalization category among its peers.
Better Fundamentals
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) | ||||
| EBITDA | (29.18 M) | ||||
| Net Income | (31.57 M) | ||||
| Cash And Equivalents | 29.68 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 14.88 M | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (26.08 M) | ||||
| Short Ratio | 0.94 X | ||||
| Earnings Per Share | (1.10) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 54 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 1.12 M | ||||
| Total Asset | 22.94 M | ||||
| Retained Earnings | (111.5 M) | ||||
| Working Capital | 4.95 M | ||||
| Z Score | -10.7 | ||||
| Net Asset | 22.94 M |
About Better Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Better Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Better Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Better Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |